Similar articles

• Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients.

  Govil A, Walsh RC, Tevar A, Alloway R, Roy-Chaudhury P, Mogilishetty G, Wall GE, Brailey P, Girnita A, Woodle ES. Govil A, et al. Clin Transpl. 2009:443-53. Clin Transpl. 2009. PMID: 20524313
• Use of bortezomib for prevention and treatment of rejection in sensitized patients.

  Hartono C, Lubetzky M, Aull MJ, Saal S, Figueiro J, Kapur S, Dadhania D. Hartono C, et al. Clin Transpl. 2009:499-503. Clin Transpl. 2009. PMID: 20524323
• Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report.

  Hamawi K, Heilman RL, Mazur MJ, Chakkera HA, Mulligan DC, Moss AA, Mekeel KL, Reddy KS. Hamawi K, et al. Clin Transpl. 2009:407-14. Clin Transpl. 2009. PMID: 20524306 No abstract available.
• Bortezomib: a new player in pre- and post-transplant desensitization?

  Lemy A, Toungouz M, Abramowicz D. Lemy A, et al. Nephrol Dial Transplant. 2010 Nov;25(11):3480-9. doi: 10.1093/ndt/gfq502. Epub 2010 Sep 8. Nephrol Dial Transplant. 2010. PMID: 20826741 Review.
• Effective therapy for acute antibody-mediated rejection with mild chronic changes: case report and review of the literature.

  Gheith O, Al-Otaibi T, Nampoory N, Halim M, Nair P, Saied T, Al-Waheeb S, Muzeirei I, Ibraheim M. Gheith O, et al. Exp Clin Transplant. 2012 Aug;10(4):406-9. doi: 10.6002/ect.2011.0153. Epub 2012 Jun 29. Exp Clin Transplant. 2012. PMID: 22746156 Review.